Which hormone therapy is a risk factor for liver cell adenoma?

Estrogen therapy is linked to an increased risk of developing liver cell adenomas. This association arises because estrogen can stimulate liver cell proliferation and increase the risk of both benign and malignant liver lesions. In women taking oral contraceptives or hormone replacement therapy that contains high doses of estrogen, there has been documented evidence of elevated liver cell adenoma incidence.

Thyroid hormone replacement does not have a direct correlation with liver adenoma formation, as it mainly affects metabolic processes and does not significantly promote hepatic cell proliferation. Progestin therapy is generally considered to have a lower risk profile regarding liver lesions compared to estrogen, although it can also have some effects on liver function. Insulin therapy primarily addresses issues related to glucose metabolism and does not have a significant correlation with liver adenoma. Therefore, estrogen therapy is the most concerning in this context due to its direct impact on liver cell dynamics.